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Stephen P. Hunger,1 K. Mignon Loh,2 K. Scott Baker,3 Kirk R. Schultz4Infants with leukemia who require hematopoietic cell transplantation (HCT) remain 1 of the most significant
challenges in pediatric stem cell transplant. Infant leukemia is characterized by a unique biology including
a predominance mixed lineage leukemia(MLL) gene rearrangement and juvenile myelomonocytic leukemia.
Moreover, the long-term effects of transplantation are particularly prominent in infants who have active en-
docrine, cardiovascular, pulmonary, neurologic, musculoskeletal, hearing, and vision development, with the
added risk of second malignant neoplasms. Currently, there is no solid basis to support allogeneic HCT as
first-line therapy for infant acute lymphoblastic leukemia-first remission (ALL-CR1), although indicated for
other infant leukemias, including juvenile myelomonocytic leukemia (JMML). The relative long-term toxicity
of total body irridiation (TBI) versus non-TBI containing preparative regimens for HCT in infants remains
controversial, with the differences, especially on neurocognitive function, unknown.
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Controversy abounds regarding the use of hemato-
poietic cell transplantation (HCT) as a therapy for leu-
kemia in infants (under age 1 year). The biology and
physiology of infants is different, and the long-term
effects of HCT are the most significant for any age
group, as growing tissues such as brain, teeth, and
the endocrine system can have an impact in a very
significant manner. Infants also have unique forms of
leukemia including a predominance of characteristic
rearrangements of the mixed lineage leukemia(MLL)
gene, associated with poor outcome, and juvenile
myelomonocytic leukemia (JMML). The following
sections will address many of these areas: including
infant acute lymphoblastic leukemia (ALL), acute my-
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The Role of HCT for Acute Leukemia in Infants
(Dr. Stephen Hunger)
The incidence of acute leukemia in infants less than
1 year of age is 35-40 cases per 1 million children, or
a total of about 150 cases/year in the United States, in-
cluding approximately 100 cases of ALL and 50 cases of
AML [1]. The outcome for infants with ALL is signifi-
cantly worse than that of older children, whereas the
outcome for infants with AML is similar to that seen
in older children. Infant leukemia is biologically distinct
from acute leukemia that occurs in older children, with
translocations of the 11q23 MLL gene present in 70%
to 80% of infant ALLs and about 50% of infant
AMLs [2]. In infant ALL, about 50% of the 11q23
translocations join MLL to AF-4 (chromosome 4q21),
20% Erythema nodosum leprosum (ENL) (chromo-
some 19p13.3), and 10% AF9 (chromosome 9p22).
AF9 is the most common MLL translocation partner
in infant AML, accounting for about 50% of cases. Sev-
eral dozen otherMLL translocation partners have been
described, with most occurring in a small percentage of
cases. The outcome of patients with different MLL
translocation partners is generally similar.
Significant controversy exists about the role of al-
logeneic HCT in infant ALL, whereas the indications
for HCT in infant AML are generally agreed to be
similar to those in older children. In the following sec-
tion, we will focus on discussing the indications for
HCT among infants with ALL in first remission (CR1).79
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older children with ALL, the cure rate for infants
with ALL is generally \50%, and has been much
lower than this for infants with MLL-rearranged
(MLL-R) ALL. For example, the 4-year event-free
survival (EFS) rate was 47% in the Interfant-99 trial
conducted from 1999 to 2005, and the presence of
any MLL translocation was 1 of the strongest predic-
tors of adverse outcome [3].
Because the outcome for infants withMLL-RALL
is so poor, HCT has long been pursued as a treatment
option for such patients. Some single-institution stud-
ies have reported good outcomes with HCT forMLL-
R infant ALL, but it is not clear whether these results
are representative of the population of infant ALL at
highest risk of treatment failure [4]. For example,
Sanders et al. [4] reported that 11 of 14 infants with
MLL-R ALL transplanted in CR1 were surviving in
first remission. However, the highest risk group of pa-
tients are those with MLL-R and age younger than 6
months at initial diagnosis, particularly those \3
months of age. The median age of the patients re-
ported by Sanders was 6.7 months at initial diagnosis,
with the youngest being 3.8 months, suggesting that
the patient population did not include many patients
with the highest risk features. Furthermore, the me-
dian age at the time of HCT was 14.1 months, with
a median interval of 5.6 months (range: 2.7-8.1
months) between diagnosis and the time of HCT. Be-
cause the rate of induction failure and early relapse has
historically been quite high in infant ALL, reports of
this type, although very encouraging, are not truly rep-
resentative because they exclude many patients that
failed prior to the time of potential HCT.
In several other large multiinstitutional studies,
HCT has no apparent benefit for infants with MLL-
R ALL. A collection of 11 international collaborative
groups examined the outcome of patients with a variety
of MLL translocations treated between 1983 and 1995
with chemotherapy or HCT [5]. To account for the
potential bias introduced in studies that look at the
outcome of patients that underwent HCT in CR1,
these analyses corrected for time to transplant by ana-
lyzing the outcome of chemotherapy patients who
were in CR1 at the median time between diagnosis
and HCT. Although not restricted to infants, among
the 256 patients with t(4;11)1 ALL any type of trans-
plant was associated with inferior disease-free (DFS)
and overall survival (OS). In a later report, this group
analyzed the outcome of 28 infants with t(4;11)1
ALL who underwent HCT and compared it to the
outcome of 103 control patients treatment with che-
motherapy [6]. Overall, the relative risk of treatment
failure (adjusted for initial white blood cell (WBC)
count and time to transplant) was 1.9 for HCT versus
chemotherapy patients. Although both of these reports
suggest that outcome is inferior for HCT versus che-motherapy for infants with MLL-R ALL, the reports
are based on treatment delivered more than a decade
ago, and are confounded by the diverse variety of che-
motherapy and transplant therapies.
The parallel Children’s Cancer Group (CCG)
1953 and Pediatric Oncology Group (POG) 9407 in-
fant ALL trials enrolled 189 infants with ALL between
1996 and 2000. The chemotherapy used was quite sim-
ilar in both trials, and each employed allogeneic HCT
for infants with MLL-R. These studies provide an op-
portunity to examine the outcomes of these 2 different
treatment strategies. Dinndorf and colleagues (manu-
script sumitted for publication) have reported the out-
come of 53 MLL-R infant ALL patients who received
HCT in CR-1 and compared it to that of 47 control
MLL-R patients who received chemotherapy, adjust-
ing for the median 143 day interval between diagnosis
and HCT. The 5-year EFS rates were 48.8% for the
HCT group and 48.7% for the chemotherapy group,
suggesting no benefit for HCT in CR1 for infants
with MLL-R ALL. However, the protocol-specified
transplant preparative regimen and graft-versus- host
disease (GVHD) prophylaxis regimen were controver-
sial, andmany patients underwentHCTusing different
regimens. Those transplanted with the protocol pre-
scribed transplant regimen (n 5 25) had a 5-year EFS
of 40% versus 56.9% (log rank value of P 5 .17) for
those transplanted using different regimens (n 5 28).JMML (DR. MIGNON LOH)
JMML is an aggressive clonal malignancy of young
children characterized by overproduction of myeloge-
nous lineage cells that infiltrate hematopoietic and
nonhematopoietic tissues [7]. The correlation between
JMML and certain inherited conditions led to impor-
tant discoveries of the abnormal proteins involved in
the perturbed signaling pathways of this disease. The
incidence of JMML is increased 200-500-fold in chil-
dren with neurofibromatosis type 1 (NF1) [8]. NF1 is
a common genetic disorder associated with neurocuta-
neous abnormalities, learning disabilities, and a predis-
position to specific benign and malignant tumors. The
association between NF1 and JMML is intriguing be-
cause theNF1 gene encodes neurofibromin, a GTPase
activating protein (GAP) for Ras, which negatively
regulates Ras output by accelerating GTP hydrolysis
[9]. Patients with NF1 and JMML demonstrate loss
of the wild-type allele in their leukemic bone marrow
with retention, and, frequently, duplication of the
mutant NF1 allele, supporting the observation that
NF1 is a tumor suppressor gene [10]. Indeed, genetic
and biochemical studies of human JMML specimens
and studies in mice have shown that NF1 and its mu-
rine homolog (Nf1) function as tumor suppressor
genes in myelogenous leukemogenesis by negatively
regulating Ras signaling [11]. Oncogenic lesions in
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syndromic JMML, again, supporting the role of hyper-
active Ras in the pathogenesis of this disorder.
Infants with Noonan Syndrome, associated with
cardiac defects, skeletal abnormalities, and variable
learning disabilities, are also at risk for developing
a transient form of JMML. Fifty percent of children
with Noonan Syndrome are known to harbor germline
lesions in PTPN11, a gene encoding a nonreceptor ty-
rosine phosphatase, SHP-2, which has also been impli-
cated in Ras signaling [7,12]. JMML bone marrows
from children without NF1 show oncogenic RAS
(25%) and PTPN11 (35%) mutations in largely mutu-
ally exclusive subsets [13]. Animal models have demon-
strated that Nf1, Kras, and Ptpn11 mutant mice all
develop fatal myeloproliferative disorders that model
JMML in vivo and in vitro [14,15]. Taken together,
these observations strongly support, in contrast to
AML, a role of hyperactive Ras in initiating JMML.
The diagnosis and treatment of patients with
JMML is challenging for clinicians. Current World
Health Organization criteria categorizes JMML as
a mixed myelodysplastic/myeloproliferative disorder,
and the diagnosis requires that a constellation of major
and minor clinical and laboratory criteria are fulfilled.
Patients must have .1000 (1  109/L) monocytes in
the circulating blood,\20% bone marrow blasts, ab-
sence of the t(9;22) or BCR/ABL fusion gene [1,16],
and at least 2 of the following: an increased fetal hemo-
globin, circulating myelogenous precursors in the pe-
ripheral blood, a total white blood cell count .10,000
(10  109/L), and growth factor hypersensitivity.
JMML myelogenous progenitors selectively form
abnormal numbers of colony-forming unit-granulo-
cyte macrophage (CFU-GM) in methylcellulose
cultures containing low concentrations of the growth
factor granulocyte-macrophage colony stimulating
factor (GM-CSF) [14,17]. In young children, the pe-
ripheral blood/bone marrow from patients with active
infections can exhibit GM-CSF hypersensitivity [18].
Thus, CFU-GM assays are not specific enough to
make the diagnosis. However, a firm molecular diag-
nosis can now be clinically implemented as mutations
in NF1, RAS, and PTPN11 are detected in up to
75% of patients with this disease.Moreover, a majority
of JMML patients display GM-CSF hypersensitivity
by hyperphosphorylating STAT5 in individual mye-
logenous cells [19].
Patients with JMML have dismal outcomes with
conventional therapy. However, the natural history
of the disease is uneven, and rare patients (usually in-
fants) may manifest a self-limited disease. Many pa-
tients with Noonan Syndrome with a high WBC
count at birth will gradually resolve over the first
year of life [20]. However, most children with de
novo JMML demonstrate a rapidly progressive disease
with failure to thrive and frequent infections. Some pa-tients progress to frank AML, most typically of the
myelomonocytic lineage. Survival after chemotherapy
alone is estimated to be \15% [16,21]. Allogeneic
HCT is the only known cure for this disease with an
EFS after HCT approximately 50% [20].
There is little data to support the use of intensive
therapy prior to HCT; however, low-dose 6-mercap-
topurine or cytarabine can ameliorate some of the
symptoms prior to therapy. Currently, the European
Working Group for Childhood Myelodysplastic Dis-
eases (EWOG-MDS) is testing the efficacy of rapid
withdrawal of post-HCT immunosuppression in older
children with JMML, as age has been shown in their
studies to be strongly correlated with an increased
risk of relapse [22]. Novel targeted approaches to ther-
apy are being evaluated in multicenter studies, includ-
ing cis-retinoic acid as a differentiating agent and the
farnesyl transferase inhibitor, R115777 [23].
Clinicians have struggled with accurate tracking of
the response to therapy usually by either a decreasing
WBC count and/or resolving splenomegaly. Evalua-
tion of response with aminimal residual disease (MRD)
assay using fluorescently based allele-specific polymer-
ase chain reaction (PCR) for 12 common Ras pathway
mutationsmay be useful once validated by theEWOG-
MDS [24].
Special Considerations and Complications
Related to the Long-TermOutcome after Infant
HCT (Dr. K. Scott Baker)
The aggressive biologic nature of infant leukemia,
combined with the unique considerations required
when performing HCT in infants, make these patients
very difficult to manage. The primary issues to con-
sider are those that will achieve the greatest chance of
cure of the leukemia, and at the same time minimize
the acute and long-term risks inherent to the transplant
procedure itself. Acute risks continue to be lessened
by advances in HLA typing, experience in the use of
alternative donor stem cell sources, and ongoing im-
provements in supportive care measures that may con-
tribute to improving DFS rates for infants undergoing
HCT in CR1 [4]. The long-term complications that
can occur after HCT in infants result from exposures
to both pretransplant chemotherapy, any central
nervous system (CNS)-directed radiation therapy
(CRT), and the transplant preparative regimen. Many
long-term complications in HCT survivors have been
associated with exposure to total body irridiation
(TBI) and, in general, most pediatric HCT physicians
feel compelled to avoid TBI for infants\12 months of
age. However, TBI-based regimens provide superior
survival for HLA-identical sibling bone marrow trans-
plants in children with ALL [25], although, in multi-
variate analysis, relapse is similar between the 2
groups. The survival benefit associated with TBI has
not been demonstrated for AML or JMML.
82 Biol Blood Marrow Transplant 15:79-83, 2009S. P. Hunger et al.There are only a handful of studies that exist re-
garding long-term complications after HCT for in-
fants, and all are limited by very small numbers of
patients, particularly for those who have not received
TBI as part of the preparative regimen. A study from
the University of Minnesota examined the long-term
follow-up of 17 children who underwent HCT for
AML or ALL less than 3 years of age [26]. Eleven pa-
tients (65%) received TBI (none had received CRT)
and 7 received preparative regimens with busulfan
(Bu) and cyclophosphamide (Cy). Median follow-up
was 11.5 years after HCT. Medical outcomes and
complications of HCT that occurred in survivors in-
cluded growth hormone deficiency (58.8%), hypothy-
roidism (35.3%), abnormal pubertal development
(11.8%), osteopenia/osteoporosis (23.5%), short stat-
ure (47.1%), dental abnormalities (47.1%), and cata-
racts (47.1%). Dyslipidemias were present in 58.8%
of patients, hyperinsulinemia in 17.6%, and hyperten-
sion in 11.8%, all characteristics of metabolic syn-
drome. Neuropsychologic testing found that
survivors performed more poorly on measures of sus-
tained attention, inhibition, response speed, and con-
sistency of attentional effort. They had poorer fine
motor speed/dexterity and visual-motor integration
skills. However, performance on measures of general
intellectual ability and academic achievement and
measures of quality of life in survivors were not differ-
ent compared to population norms. Despite the fact
that two-thirds of patients in this study received TBI
and did exhibit a range of neuropsychologic deficits,
most were functioning at an average or above level ac-
ademically. This study was unable to make any defini-
tive comparisons between TBI and non-TBI-based
preparative regimens. A similar study from St. Jude
Children’s Research Hospital reported on the late se-
quelae of 34 children diagnosed with acute leukemia
at age 12 months or younger [27]. These patients
were divided into 3 groups based upon treatment expo-
sures: chemotherapy alone (n 5 10, group A), chemo-
therapy and CRT (n 5 17, group B), and
chemotherapy, HCT, and CRT (n 5 7, [cranial only
n 5 2, craniospinal n 5 1, TBI n 5 4] group C). For
growth, patients in group B had a greater decrease in
height Z-scores, compared to patients in group A,
with the greatest decrease in group C with 71% of
them falling by .2 standard deviations. Other endo-
crine abnormalities included hypothyroidism (21%,
from groups B and C only), precocious puberty
(from groups B and C), and delayed puberty after
testicular radiation. Neuropsychologic evaluations
found that 50% required special tutoring or special ed-
ucation classes. Patients in groups B and C had higher
incidences of academic difficulties (59% and 86%, re-
spectively) compared to 10% in group A. The odds of
academic difficulties increased by 18% for each month
younger in age at the time of CRT.Other published data on long-term outcomes after
HCT in children do not focus on the impact to infants.
The only late effects study with comparative data ex-
amining the impact of conditioning regimens without
TBI in allogeneic HCT comes from a study of 45 pa-
tients from 17 French transplant centers [28]. Of the
45 patients studied, 26 received Bu-based regimens
and 19 TBI. The mean cumulative changes in height
SD score was significantly greater after TBI exposure,
the probability of hypothyroidism was significantly
greater after TBI, and the risk of primary ovarian fail-
ure was not different in the Bu compared to the TBI
group and males were just as likely to have normal pu-
berty regardless of conditioning. The probability of
cataracts was 70% in the TBI group versus none in
the Bu group. Unfortunately, neuropsychologic com-
plications were not addressed.
It is also important to note that recent studies from
the Childhood Cancer Survivor Study have focused on
25-year follow-up among survivors of acute lympho-
blastic [29] and AML [30] who have not received
HCT and have found the odds of reporting chronic
medical conditions in ALL survivors was 2.8 times,
and severe or life-threatening conditions 3.6 times
more likely, than reported by siblings. The cumulative
incidence of any chronic medical condition was 65%,
and for severe, life-threatening conditions was 21.3%
(the cumulative incidence was also higher in irradiated
survivors compared to nonirradiated survivors). For
AML survivors, half reported a chronic medical
condition, including over 16% with a severe or life-
threatening condition compared to 5.8% of siblings.
The most commonly reported conditions included
endocrine, second, malignant neoplasms (cumulative
incidence in AML was 1.7% at 20 years and was
5.2% at 25 years for ALL survivors) cardiovascular,
pulmonary, neurologic, musculoskeletal, and hear-
ing/vision abnormalities.
There are special long-term follow-up consider-
ations that should be taken into account for these in-
fants after HCT. A detailed treatment history must be
obtained including all treatment received before
HCT (including radiation therapy), and this must
be considered in conjunction with the specific trans-
plant preparative regimen utilized. These patients
should be closely monitoring for growth and develop-
ment up through puberty. Routine monitoring of en-
docrine function, bone health, cardiac function,
pulmonary function, dentition, and for second can-
cers should be done. Additionally, periodic neuropsy-
chologic screening to identify deficits should be
performed to allow for early interventions. HCT sur-
vivors are also at risk at an early age for dyslipidemia,
hypertension, insulin resistance, etc., which poten-
tially may increase their risk for the premature devel-
opment of atherosclerotic vascular disease and
diabetes.
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outcomewith either chemotherapy orHCT. Although
there are significant caveats to the existing data, there
is no overall advantage for HCT, and this should not
be considered the routine treatment of choice. How-
ever, significant controversy still exists with some
treatment groups advocating HCT in CR1 for subsets
of infants with MLL-R ALL. JMML remains a diffi-
cult disease to diagnose and treat prior to HCT.
Recent advances in technology make it possible to
more easily diagnose and track patients on therapy.
The molecular genetics and the resulting biochemical
perturbations reveal potential targets for therapeutic
interventions. At this point more data are needed to
better define the impact of non-TBI conditioning reg-
imens in infants undergoing HCT upon the ultimate
development of chronic medical conditions. The
risk/benefit ratio in this vulnerable population needs
to be carefully considered.ACKNOWLEDGMENTS
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